CEVI 📈 CellaVision AB - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000683484
CEVI: Hematology Instruments, Analyzers, Software, Reagents, Blood Analysis
CellaVision AB is a company that specializes in developing and marketing innovative solutions for the analysis of blood and body fluids. Their product portfolio includes a range of instruments, software, and reagents designed to automate and simplify laboratory processes, particularly in the field of hematology. For instance, their CellaVision DM1200 and CellaVision DM9600 systems are designed to automate blood and body fluid differentials, while their CellaVision DC-1 analyzer enables low-volume hematology labs to implement digital methodology for blood cell analysis.
The company's product line also includes the DIFF-Line system, which automates and digitizes the process of analyzing peripheral blood smears. Additionally, they offer a range of software applications, such as the CellaVision Peripheral Blood Application, CellaVision Advanced RBC Application, and CellaVision Body Fluid Application, which enable laboratories to automate, standardize, and simplify morphological examinations of peripheral blood smears and body fluid preparations. These applications are designed to improve laboratory efficiency and accuracy, ultimately leading to better patient outcomes.
CellaVision AB also provides software solutions for remote review and collaboration, such as the CellaVision Remote Review Software, which removes geographical constraints from the smear review process. Furthermore, their CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites, while the CellaVision Proficiency Software is a web-based tool designed to help laboratory managers assess and promote staff competency in cell morphology. The company's CellAtlas platform combines mini lectures with an extensive cell image library, providing a valuable resource for laboratory professionals.
In addition to their software and instrument offerings, CellaVision AB also provides reagents for identifying cell and tissue morphology, parasites, and bacteria in diagnosing various diseases. Their instrument portfolio includes the RAL SmearBox, RAL Stainbox, and RAL Stainer, which are designed to support laboratory workflows. The company's products are sold to hospital and commercial laboratories, and they have established a strong presence in the global market. With a history dating back to 1994, CellaVision AB is headquartered in Lund, Sweden, and is listed on the stock exchange with the ISIN code SE0000683484.
As a company operating in the health care equipment industry, CellaVision AB is committed to delivering high-quality products and solutions that meet the evolving needs of laboratories and healthcare professionals. Their focus on innovation, customer satisfaction, and regulatory compliance has enabled them to establish a strong reputation in the market. With a web presence at https://www.cellavision.com, the company provides easy access to information about their products, services, and company updates, making it a valuable resource for customers, investors, and industry partners.
Additional Sources for CEVI Stock
CEVI Stock Overview
Market Cap in USD | 445m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
CEVI Stock Ratings
Growth 5y | -41.4% |
Fundamental | 81.5% |
Dividend | 54.3% |
Rel. Strength Industry | -116 |
Analysts | - |
Fair Price Momentum | 178.55 SEK |
Fair Price DCF | 165.33 SEK |
CEVI Dividends
Dividend Yield 12m | 1.10% |
Yield on Cost 5y | 0.66% |
Annual Growth 5y | 31.61% |
Payout Consistency | 83.9% |
CEVI Growth Ratios
Growth Correlation 3m | -87.6% |
Growth Correlation 12m | 16.3% |
Growth Correlation 5y | -56.5% |
CAGR 5y | -9.44% |
CAGR/Mean DD 5y | -0.26 |
Sharpe Ratio 12m | 0.13 |
Alpha | -17.55 |
Beta | 0.67 |
Volatility | 44.44% |
Current Volume | 18.6k |
Average Volume 20d | 13.6k |
As of January 15, 2025, the stock is trading at SEK 210.50 with a total of 18,609 shares traded.
Over the past week, the price has changed by -0.97%, over one month by -9.93%, over three months by -30.38% and over the past year by -0.46%.
Yes, based on ValueRay Fundamental Analyses, CellaVision AB (ST:CEVI) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.54 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CEVI as of January 2025 is 178.55. This means that CEVI is currently overvalued and has a potential downside of -15.18%.
CellaVision AB has no consensus analysts rating.
According to ValueRays Forecast Model, CEVI CellaVision AB will be worth about 196.4 in January 2026. The stock is currently trading at 210.50. This means that the stock has a potential downside of -6.7%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 267.5 | 27.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 196.4 | -6.7% |